Clinical Therapeutic Effect of Praziquantel Injection on Buffalo Schistosomiasis

To observe the clinical therapeutic effect of 30% praziquantel injection on buffalo schistosomiasis, the sick buffalos naturally infected with Schistosoma japonicum were selected by miracidium hatching method. In experimental clinical trials, sick buffalos were randomly divided into five groups, high-dose (20 mg/kg), middle-dose (10 mg/kg) and low-dose (5 mg/kg) praziquantel injection groups, praziquantel tablet group (30 mg/kg) and positive control group. After the treatment of 30 d, the negative conversion rate of miracidium were 100.0%, 100.0%, 77.8% and 85.7%, respectively, in praziquantel injection groups with the high, middle and low dose and oral medication group. In expanded clinical trials, the sick buffalos were randomly divided into two groups, praziquantel injection group (10 mg/kg, i.m.) and praziquantel tablet group (30 mg/kg). The results showed that, the negative conversion rate of miracidium were all 100% in the former 52 patients and the latter 6 patients after 30 d. The research confirmed that praziquantel injection was significantly effective in the treatment of buffalo schistosomiasis and convenient for administration. It was concluded that 30% praziquantel injection could replace the traditional oral praziquantel tablet for the treatment of buffalo schistosomiasis, and the recommended dose was 10 mg/kg.